Clinical Trial

A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine

Study acronym: S4V03
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
In this challenge study, the bioconjugate candidate vaccine Shigella4V2 will be tested for its ability to induce an immune response that protects healthy adult volunteers from infection with a wild-type Shigella sonnei strain compared to participants receiving placebo.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-04-14
Trial Details
NCT Number NCT06615375
Lead Sponsor LimmaTech Biologics AG
Collaborators: Emory University, Johns Hopkins Bloomberg School of Public Health, Children's Hospital Medical Center, Cincinnati
Conditions Shigellosis
Enrollment 120 participants
Start Date 2024-11-12
Primary Completion 2026-04-14 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2026-07-16